Compare PERI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | EDIT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.3M | 432.8M |
| IPO Year | 2005 | 2016 |
| Metric | PERI | EDIT |
|---|---|---|
| Price | $8.42 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $14.50 | $5.30 |
| AVG Volume (30 Days) | 600.7K | ★ 3.2M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $9.98 | N/A |
| Revenue Next Year | $2.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $7.63 | $1.66 |
| 52 Week High | $11.44 | $4.54 |
| Indicator | PERI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 41.13 |
| Support Level | $8.27 | $2.49 |
| Resistance Level | $10.43 | $2.63 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 60.46 | 8.33 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.